|
Mar 28
|
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Mar 27
|
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript
|
|
Mar 27
|
Q4 2023 Acumen Pharmaceuticals Inc Earnings Call
|
|
Mar 26
|
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
|
|
Mar 21
|
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
|
|
Mar 21
|
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
|
|
Mar 19
|
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
|
|
Mar 18
|
15 Best Anti-Aging Foods for Youthful Skin
|
|
Mar 12
|
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
|
|
Mar 8
|
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
|
|
Jan 4
|
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Nov 7
|
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
|
|
Nov 7
|
Q3 2023 Halozyme Therapeutics Inc Earnings Call
|
|
Nov 6
|
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
|
|
Nov 6
|
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
|
|
Nov 2
|
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
|
|
Jul 19
|
Acumen Announces Pricing of Upsized $130 Million Public Offering
|
|
Jul 18
|
Why Shares of Acumen Pharmaceuticals Are Down Tuesday
|
|
Jul 17
|
Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
Jul 17
|
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
|